Erik Henke
Overview
Explore the profile of Erik Henke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
2031
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoffmann H, Wartenberg M, Vorlova S, Karl-Scholler F, Kallius M, Reinhardt O, et al.
Oncogene
. 2024 Aug;
43(35):2661-2676.
PMID: 39095583
Blood vessels in tumors are often dysfunctional. This impairs the delivery of therapeutic agents to and distribution among the cancer cells. Subsequently, treatment efficacy is reduced, and dose escalation can...
2.
Ascheid D, Baumann M, Pinnecker J, Friedrich M, Szi-Marton D, Medved C, et al.
Nat Commun
. 2024 Apr;
15(1):3599.
PMID: 38678014
Targeting the supportive tumor microenvironment (TME) is an approach of high interest in cancer drug development. However, assessing TME-targeted drug candidates presents a unique set of challenges. We develop a...
3.
Ascheid D, Baumann M, Funke C, Volz J, Pinnecker J, Friedrich M, et al.
Biol Direct
. 2023 Mar;
18(1):10.
PMID: 36922848
In tumor therapy anti-angiogenic approaches have the potential to increase the efficacy of a wide variety of subsequently or co-administered agents, possibly by improving or normalizing the defective tumor vasculature....
4.
Upcin B, Henke E, Kleefeldt F, Hoffmann H, Rosenwald A, Irmak-Sav S, et al.
Cells
. 2021 Aug;
10(7).
PMID: 34359889
Blocking tumor vascularization has not yet come to fruition to the extent it was hoped for, as angiogenesis inhibitors have shown only partial success in the clinic. We hypothesized that...
5.
Solimando A, Da Via M, Leone P, Borrelli P, Croci G, Tabares P, et al.
Haematologica
. 2020 May;
106(7):1943-1956.
PMID: 32354870
Interactions of malignant multiple myeloma (MM) plasma cells (MM-cells) with the microenvironment control MM-cell growth, survival, drug-resistance and dissemination. As in MM microvascular density increases in the bone marrow (BM),...
6.
Henke E, Nandigama R, Ergun S
Front Mol Biosci
. 2020 Mar;
6:160.
PMID: 32118030
Solid tumors are complex organ-like structures that consist not only of tumor cells but also of vasculature, extracellular matrix (ECM), stromal, and immune cells. Often, this tumor microenvironment (TME) comprises...
7.
Worsdorfer P, Dalda N, Kern A, Kruger S, Wagner N, Kwok C, et al.
Sci Rep
. 2019 Nov;
9(1):15663.
PMID: 31666641
Organoids derived from human pluripotent stem cells are interesting models to study mechanisms of morphogenesis and promising platforms for disease modeling and drug screening. However, they mostly remain incomplete as...
8.
Aktas B, Upcin B, Henke E, Padmasekar M, Qin X, Ergun S
Stem Cells Int
. 2019 Jun;
2019:1608787.
PMID: 31191665
Pluripotent stem cells give rise to reproductively enabled offsprings by generating progressively lineage-restricted multipotent stem cells that would differentiate into lineage-committed stem and progenitor cells. These lineage-committed stem and progenitor...
9.
Volz J, Mammadova-Bach E, Gil-Pulido J, Nandigama R, Remer K, Sorokin L, et al.
Blood
. 2019 Apr;
133(25):2696-2706.
PMID: 30952674
Maintenance of tumor vasculature integrity is indispensable for tumor growth and thus affects tumor progression. Previous studies have identified platelets as major regulators of tumor vascular integrity, as their depletion...
10.
Nandigama R, Upcin B, Aktas B, Ergun S, Henke E
Histochem Cell Biol
. 2018 Oct;
150(6):631-648.
PMID: 30361778
As in the systemic treatment of any disease, it is crucial for anti-cancer drugs to reach their target at a sufficient that is a therapeutically effective dose. However, unlike normal...